Neurogene Inc. (NGNE)

Market Cap	301.99M
Revenue (ttm)	n/a
Net Income (ttm)	-84.39M
Shares Out	14.27M
EPS (ttm)	-4.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,562
Open	19.52
Previous Close	19.22
Day's Range	19.52 - 21.59
52-Week Range	6.88 - 74.49
Beta	n/a
Analysts	Strong Buy
Price Target	41.86 (+97.83%)
Earnings Date	Aug 11, 2025

About NGNE

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: NGNE
• Website: https://www.neurogene.com

Analyst Forecast

According to 7 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price target is $41.86, which is an increase of 97.83% from the latest price.

Price Target

$41.86

(97.83% upside)

Analyst Consensus: Strong Buy